Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation

Neuroscience

Volumn 256, Issue , 2014, Pages 137-146

  Chen, S ^a   An, F M ^a   Yin, L ^a   Liu, A R ^b   Yin, D K ^c   Yao, W B ^a   Gao, X D ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Advanced glycation end products; Diabetes related Alzheimer's disease; Glucagon like peptide 1; Glycogen synthase kinase 3 ; High glucose; Tau

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE; BOVINE SERUM ALBUMIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLYCOALDEHYDE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; TAU PROTEIN; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NEUROPROTECTIVE AGENT; SERINE; WORTMANNIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; EMBRYO; HIPPOCAMPUS; HYPERGLYCEMIA; IN VITRO STUDY; NEUROPROTECTION; NONHUMAN; PC12 CELL; PRIORITY JOURNAL; PROTEIN HYPERPHOSPHORYLATION; PROTEIN MODIFICATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL EMBRYO; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NERVE CELL; PHOSPHORYLATION; TOXICITY; WISTAR RAT;

ANDROSTADIENES; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOSYLATION END PRODUCTS, ADVANCED; HIPPOCAMPUS; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RATS; RATS, WISTAR; SERINE; SERUM ALBUMIN, BOVINE; TAU PROTEINS;

EID: 84888058168     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.038     Document Type: Article

References (38)

1. Ashe K.H., Zahs K.R. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
2. Chen Y., Cao C.P., Li C.R., Wang W., Zhang D., Han L.L., Zhang X.Q., Kim A., Kim S., Liu G.L. Ghrelin modulates insulin sensitivity and tau phosphorylation in high glucose-induced hippocampal neurons. Biol Pharm Bull 2010, 33:1165-1169.
3. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 2012, 34:1211-1224.
4. Clodfelder-Miller B.J., Zmijewska A.A., Johnson G.V., Jope R.S. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006, 55:3320-3325.
5. Cunha M.P., Martín-de-Saavedra M.D., Romero A., Parada E., Egea J., Del Barrio L., Rodrigues A.L., López M.G. Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: involvement of intracellular signaling pathways. Neuroscience 2013, 238:185-194.
6. Del Ser T. Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor. Alzheimers Dement 2010, 6:S147.
7. Deng Y.Q., Xu G.G., Duan P., Zhang Q., Wang J.Z. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 2005, 26:519-526.
8. Ghaboura N., Tamareille S., Ducluzeau P.H., Grimaud L., Loufrani L., Croué A., Henrion, Tourmen Henrion D., Furber A., Prunier F. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic Res Cardiol 2011, 106:147-162.
9. Grimm S., Ott C., Hörlacher M., Weber D., Höhn A., Grune T. Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1. Biochem J 2012, 448:127-139.
10. Guimarães E.L., Empsen C., Geerts A., van Grunsven L.A. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 2010, 52:389-397.
11. Hsu Y.Y., Tseng Y.T., Lo Y.C. Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. Toxicol Appl Pharmacol 2013, 272:787-796.
12. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat Rev Neurosci 2010, 11:539-551.
13. Janson J., Laedtke T., Parisi J.E., O'Brien P., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
14. Kim D.H., Huh J.W., Jang M., Suh J.H., Kim T.W., Park J.S., Yoon S.Y. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiol Dis 2012, 46:52-58.
15. Ko S.Y., Lin Y.P., Lin Y.S., Chang S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 2010, 49:474-480.
16. Kosaraju J., Gali C.C., Khatwal R.B., Dubala A., Chinni S., Holsinger R.M., Madhunapantula V.S., Muthureddy Nataraj S.K., Basavan D. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 2013, 72:291-300.
17. Kuo T.Y., Huang C.L., Yang J.M., Huang W.J., Huang N.K., Chen Y.W., Lin R.J., Yang Y.C. The role of ribosylated-BSA in regulating PC12 cell viability. Cell Biol Toxicol 2012, 28:255-267.
18. Li Y., Chigurupati S., Holloway H.W., Mughal M., Tweedie D., Bruestle D.A., Mattson M.P., Wang Y., Harvey B.K., Ray B., Lahiri D.K., Greig N.H. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012, 7:e32008.
19. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010, 19:1205-1219.
20. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 2012, 33:1400-1410.
21. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 2009, 106:1285-1290.
22. Llorens-Martín M., Fuster-Matanzo A., Teixeira C.M., Jurado-Arjona J., Ulloa F., Defelipe J., Rábano A., Hernández F., Soriano E., Avila J. GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol Psychiatry 2013, 10.1038/mp.2013.4.
23. Makita Z., Vlassara H., Cerami A., Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992, 267:5133-5138.
24. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., Frank B.P., Thomas S., Chadwick W.A., Greig N.H., Bates G.P., Sathasivam K., Bernier M., Maudsley S., Mattson M.P., Egan J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328.
25. Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., Burk U., Onichtchouk D., Dohrmann C., Austen M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007, 282:12030-12037.
26. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999, 53:1937-1942.
27. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002, 300:958-966.
28. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72:603-612.
29. Qian Y.F., Wang H., Yao W.B., Gao X.D. Aqueous extract of the Chinese medicine, Danggui-Shaoyao-San, inhibits apoptosis in hydrogen peroxide-induced PC12 cells by preventing cytochrome c release and inactivating of caspase cascade. Cell Biol Int 2008, 32:304-311.
30. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
31. Serenó L., Coma M., Rodríguez M., Sánchez-Ferrer P., Sánchez M.B., Gich I., Agulló J.M., Pérez M., Avila J., Guardia-Laguarta C., Clarimón J., Lleó A., Gómez-Isla T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009, 35:359-367.
32. Shelton S.B., Johnson G.V. Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. J Neurosci Res 2001, 66:203-213.
33. Tokutake T., Kasuga K., Yajima R., Sekine Y., Tezuka T., Nishizawa M., Ikeuchi T. Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J Biol Chem 2012, 287:35222-35233.
34. Wang Y., Zhang J.X., Du X.X., Zhao L., Tian Q., Zhu L.Q., Wang S.H., Wang J.Z. Temporal correlation of the memory deficit with Alzheimer-like lesions induced by activation of glycogen synthase kinase-3. J Neurochem 2008, 106:2364-2374.
35. Wang H.W., Mizuta M., Saitoh Y., Noma K., Ueno H., Nakazato M. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells. Metabolism 2011, 60:1081-1089.
36. Wang X., Song Y., Chen L., Zhuang G., Zhang J., Li M., Meng X.F. Contribution of single-minded 2 to hyperglycaemia-induced neurotoxicity. Neurotoxicology 2013, 35:106-112.
37. Yoon S.Y., Park J.S., Choi J.E., Choi J.M., Lee W.J., Kim S.W., Kim D.H. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol Dis 2010, 40:449-455.
38. Zmatliková Z., Sedláková P., Lacinová K., Eckhardt A., Pataridis S., Mikšík I. Non-enzymatic posttranslational modifications of bovine serum albumin by oxo-compounds investigated by high-performance liquid chromatography-mass spectrometry and capillary zone electrophoresis-mass spectrometry. J Chromatogr A 2010, 1217:8009-8015.